June 2021, Vol. 11(6)

KALAMAZOO, Mich.—(BUSINESS WIRE)—Kalexsyn Inc. (Kalexsyn), a world-class CRO and CDMO providing chemistry services to the biotechnology and pharmaceutical industry, announces that its Board of Directors appointed Brian Eklov to succeed Robert Gadwood, who is retiring, as Chief Executive Officer and Board member.

The CEO appointment was effective on May 18. Brian Eklov will focus on Kalexsyn’s sustainable growth, leveraging competencies and operational efficiency within the Dipharma Group, which acquired Kalexsyn in 2018 through its American subsidiary Dipharma, Inc.

In 2003, Robert Gadwood and David Zimmerman founded Kalexsyn and over the years the Company has become a world-class Contract Research Organization (CRO), providing innovative chemistry services to the biotechnology and pharmaceutical companies. After the acquisition of the Company by the Dipharma Group, Robert Gadwood has continued to lead the Company.

“We are delighted to have Brian as Kalexsyn’s next CEO,” said Jorge Nogueira, Chairman of Kalexsyn’s Board of Directors and CEO of Dipharma Francis. “He has deep knowledge of the industry dynamics and has been an outstanding R&D director at Kalexsyn since 2016. With his commitment and determination, we will continue optimizing Dipharma’s value proposition to reinforce our presence in the U.S. Market, expanding the range of services offered to our customers, from discovery research through commercialization.” Eklov joined the company as a research scientist in 2007 after receiving his Ph.D. from the University of Minnesota and a post-doctoral appointment at the University of Illinois, where he trained in synthetic organic chemistry. Brian became Associate Director of Chemistry at Kalexsyn in 2012 and then Director of Chemistry in 2016 and is an active participant in governance of the American Chemical Society.